[Skip to the guide](#reading) [tesamorelin injections](/) Questions behind the belly-fat shot [Questions to take](/help-desk/) [Welcome desk](/) On this desk [Start with the conditions that rule it out.](#excluded) [Problems reported in the main trials.](#effects) [When to get help promptly.](#help-now) All chapters [Welcome desk](/) [Quick brief](/quick-brief/) [Finding care](/care-desk/) [The care visit](/visit-desk/) [Licence checks](/licence-desk/) [The money desk](/money-desk/) [Insurance & help](/coverage-desk/) [Body checks](/safety-desk/) [Offer checks](/warning-signs/) [Trial results](/research-notes/) [Questions to take](/help-desk/) [The source desk](/source-desk/) Read a little. Ask a better question. [Welcome desk](/) Body checks Body checks · Care handbook # What can go wrong, and who needs a closer look? An approval is not a promise that a medicine fits every person. These are the main cautions in the tesamorelin label, in words you can bring to a visit. ## Start with the conditions that rule it out. The September 2026 label rules tesamorelin out during pregnancy and for people with active cancer. It also rules it out with known allergy to tesamorelin or its other ingredients. Growth hormone is a body signal that helps build tissue and break down fat in adults. The label also rules it out if the pituitary, the gland that releases growth hormone, has been removed or damaged. Tell the prescriber about pituitary surgery or tumours, radiation treatment to the head, or a head injury. The label lists these among reasons that the gland’s control system may not work properly. A past treated cancer needs a careful weighing of possible benefit against the chance of the cancer returning. The label raises that concern; it does not establish that tesamorelin causes cancer. Fair question ### What if I am an older adult? The September 2026 label gives no information on use in people older than 65. It does not approve use in children. For someone aged 80, this leaves a gap in what the label can tell you about safety and benefit. Age over 65 is not itself one of the label’s listed reasons that rule the medicine out. Ask the prescriber how that missing information affects the decision in your case. Ask the prescriber to go through your own history, including pregnancy plans and other medicines. ## Problems reported in the main trials. Tesamorelin can cause the body to hold fluid, with swelling, joint discomfort, or tingling linked to a pinched wrist nerve. It can also raise blood sugar. The main trials used a blood sugar test called HbA1c. A result high enough to suggest diabetes occurred in 5 in 100 people on tesamorelin, compared with 1 in 100 on the dummy injection. Those figures count high test results; they do not tell us that each person received a confirmed diabetes diagnosis. A dummy injection is a placebo: the comparison shot that contains no study medicine. The label’s table of unwanted reactions reported problems where the shot went in for 17 in 100 people on tesamorelin, compared with 6 in 100 on placebo. Redness and itching at that spot are examples named in the label. Another section counts reactions where the shot went in more broadly: 25 in 100 on tesamorelin and 14 in 100 on placebo over 26 weeks. The two counts use different definitions; do not add them together. IGF-1 is a body signal that helps tissues grow. Tesamorelin can raise its level far above normal. The label says the effects of long-lasting high IGF-1 levels are unknown. [See the checks described in the label](/visit-desk/) ## When to get help promptly. The tesamorelin label tells patients with a suspected allergic reaction to stop treatment and seek prompt medical attention. Breathing trouble or a swollen tongue may signal a severe allergic reaction. That is an emergency. If symptoms are severe, contact emergency services or get to the closest emergency department. The label warns about life-threatening illness, such as severe problems after major surgery, a serious accident, or breathing failure. Because tesamorelin makes the body release growth hormone, it says prescribers should consider stopping it in these situations. Studies of large amounts of growth hormone found more deaths in these very ill patients. Those studies used growth hormone itself; the tesamorelin label uses that finding as a reason for caution. If you become seriously ill, tell the treating team you take tesamorelin and ask them whether it should be stopped. Growth hormone can change how quickly the liver breaks down some other medicines. That can change their effect, so the label tells prescribers to watch for problems when medicines are taken together. Ask the clinician how these cautions apply to your history and other medicines. Open the source drawer These cautions come from the September 2026 drug label. Ask the prescriber to explain which apply to your health history and other medicines. - [Tesamorelin (EGRIFTA WR): cautions and reactions](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75) - [Tesamorelin (EGRIFTA SV): cautions and reactions](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224) - [MedlinePlus: severe allergic reactions](https://medlineplus.gov/ency/article/000844.htm) Weigh the belly-fat offer carefully Bring your health history and medicine list to the prescriber. Keep a clear way to get help if a problem appears. [Previous desk Insurance & help](/coverage-desk/) [Next desk Offer checks](/warning-signs/) This handbook helps you make sense of tesamorelin care. The site sells no medicine and does not operate as a clinic. [Read as text](/safety-desk/index.md) [The source desk](/source-desk/) [Text index](/llms.txt)